Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative-Reference-Cited by-同舟云学术

Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative

Published:2020-05-30 Issue:4 Volume:108 Page:817-825
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Happich Michael¹,Brnabic Alan²,Faries Douglas³,Abrams Keith⁴,Winfree Katherine B.³,Girvan Allicia³,Jonsson Pall⁵,Johnston Joseph³,Belger Mark¹,

Affiliation:

1. Lilly Research Centre Eli Lilly and Company Surrey UK

2. Eli Lilly and Company Sydney New South Wales Australia

3. Lilly Corporate Center Eli Lilly and Company Indianapolis Indiana USA

4. Department of Health Sciences University of Leicester Leicester UK

5. National Institute for Health and Care Excellence (NICE) Manchester UK

Funder

Eli Lilly and Company

Seventh Framework Programme

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1854

Reference32 articles.

1. UMC Utrecht.Welcome to GetReal. IMI GetReal (2019). Accessed September 17 2019.

2. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

3. The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias

4. United Kingdom National Institute for Health and Care Excellence (NICE).Guide to the processes of technology appraisal. Section 2.4.32 (April2018). Accessed September 17 2019.

5. United Kingdom National Institute for Health and Care Excellence (NICE).Guide to methods of technology appraisal 2013: process and methods. Sections 3.2.2 and 3.3.3 (April2013). Accessed September 17 2019.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention;Journal of Managed Care & Specialty Pharmacy;2023-12

2. Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments;PharmacoEconomics;2023-10-27

3. Transportability of two heart failure trials to a disease registry using individual patient data;Journal of Clinical Epidemiology;2023-10

4. Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness;Contemporary Clinical Trials Communications;2023-06

5. Reweighting estimators to extend the external validity of clinical trials: methodological considerations;Journal of Biopharmaceutical Statistics;2023-01-23